Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria

Leukemia and Lymphoma

Volumn 48, Issue 8, 2007, Pages 1522-1530

  Brepoels, Lieselot ^a   Stroobants, Sigrid ^a   De Wever, Walter ^a   Spaepen, Karoline ^a   Vandenberghe, Peter ^a   Thomas, Jose ^a   Uyttebroeck, Anne ^a   Mortelmans, Luc ^a   De Wolf Peeters, Christiane ^a   Verhoef, Gregor ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CT; Non Hodgkin's lymphoma; PET; Response assessment

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; WORKSHOP;

ADOLESCENT; ADULT; AGED; BURKITT LYMPHOMA; FLUORODEOXYGLUCOSE F18; HUMANS; INTERNATIONAL COOPERATION; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34547978802     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701474365     Document Type: Article

References (19)

1. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol, 17, pp. 1244-1253.
2. Coiffier, B. (1999) How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients. Ann Oncol, 10, pp. 1141-1143.
3. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J. and Vandenberghe, P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol, 19, pp. 414-419.
4. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed classical computed tomography scan imaging. Blood, 94, pp. 429-433.
5. Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J. and Kittner, T. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol, 115, pp. 793-800.
6. Zinzani, P. L., Fanti, S., Battista, G., Tani, M., Castellucci, P. and Stefoni, V. (2004) Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer, 91, pp. 850-854.
7. Mikhaeel, N. G., Timothy, A. R., O'Doherty, M. J., Hain, S. and Maisey, M. N. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma, 39, pp. 543-553.
8. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L. and Horning, S. J. (2007) Revised response criteria for malignant lymphoma. J Clin Oncol, 25, pp. 579-586.
9. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. and Guermazi (2007) Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project (IHP) in Lymphoma. J Clin Oncol, 25, pp. 571-578.
10. Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D. and Erdi, Y. E. (2005) Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 4643-4651.
11. Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M. F. and Rigo, P. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol, 12, pp. 825-830.
12. Najjar, F., Hustinx, R., Jerusalem, G., Fillet, G. and Rigo, P. (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm, 16, pp. 297-304.
13. Barosi, G., Carella, A., Lazzarino, M., Marchetti, M., Martelli, M. and Rambaldi, A. (2005) Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: Practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica, 90, pp. 1236-1257.
14. Armitage, J. (2005) Staging Non-Hodgkin lymphoma. CA Cancer J Clin, 55, pp. 368-376.
15. Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. and Cleary, M. L. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood, 84, pp. 1361-1392.
16. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 329, pp. 987-994.
17. Atra, A., Imeson, J. D., Hobson, R., Gerrard, M., Hann, I. M. and Eden, O. B. (2000) Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): Results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer, 82, pp. 1396-1402.
18. Kaplan, E. S. and Meier, P. (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc, 58, pp. 457-481.
19. Freudenberg, L. S., Antoch, G., Schutt, P., Beyer, T., Jentzen, W. and Muller, S. P. (2004) FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging, 31, pp. 325-329.